Submission of transcript of earnings call on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

AI summary - Consolidated total income grew 36% y-y to INR668 Cr in Q1 FY27 - EBITDA rose 35% y-y to INR175 Cr; margin steady at 26% - PAT increased 6% y-y to INR51 Cr; margin approx 8% - Jayhawk contributed ~20-22% of revenue with 19-20% EBITDA margin - Commercialized ETFA via flow chemistry, a global first, targeting $0.5bn market - Signed USD300mn LoI with BASQUEVOLT for specialty chemical over 10 years - Bliss GVS Pharma acquisition progressing; expected close H1 Sep 2026 - Capex largely complete; FY27 capex guided at INR70-80 Cr - Working capital stable; improvement expected in FY27 - Semiconductor and performance materials segments showing strong growth and pipeline